Cargando…

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study

Detalles Bibliográficos
Autores principales:	Erba, Paola A., Maecke, Helmut, Mikolajczak, Renata, Decristoforo, Clemens, Zaletel, Katja, Maina-Nock, Theodosia, Peitl, Petra Kolenc, Garnuszek, Piotr, Froberg, Alida, Goebel, Georg, de Jong, Marion, Jabrocka-Hybel, Agata, Konijnenberg, Mark, Virgolini, Irena, Nock, Berthold, Lenda-Tracz, Wioletta, Pawlak, Dariusz, Rangger, Christine, Trofimiuk-Müldner, Małgorzata, Sowa–Staszczak, Anna, Tomaszuk, Monika, von Guggenberg, Elisabeth, Scarpa, Lorenza, Hubalewska–Dydejczyk, Alicja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347971/ https://www.ncbi.nlm.nih.gov/pubmed/30516761 http://dx.doi.org/10.20452/pamw.4387

Ejemplares similares

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

[(111)In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
por: Lezaic, Luka, et al.
Publicado: (2022)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Imaging with [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH(2)]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report
por: Pach, D., et al.
Publicado: (2013)

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

(99m)Tc Labeled Glucagon-Like Peptide-1-Analogue ((99m)Tc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma
por: Sowa-Staszczak, Anna, et al.
Publicado: (2016)

The development of guidelines for management of thyroid diseases in pregnancy – current status
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2015)

Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
por: Fani, Melpomeni, et al.
Publicado: (2020)

How much of the predisposition to Hashimoto’s thyroiditis can be explained based on previously reported associations?
por: Jabrocka-Hybel, A., et al.
Publicado: (2018)

Comment on: Somatostatin receptor SPECT
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2012)

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
por: Laverman, Peter, et al.
Publicado: (2011)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

FRI491 The Impact Of Insulin Resistance On Thyroid Function In Pregnancy
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2023)

FRI489 The Interplay Between Thyroid Nodular Disease And Insulin Resistance Indices In Pregnant Women
por: Jerzy Nowak, Andrzej, et al.
Publicado: (2023)

MON-013 Nutritional Approach To Autoimmune Thyroiditis (AIT) - The Patients’ And Medical Professionals’ View.
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2019)

PSAT384 Familial Non-Medullary Thyroid Cancer — Does The Number Of Alanine Residues In The FOXE1 Gene Play A Role?
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2022)

AIP gene germline variants in adult Polish patients with apparently sporadic pituitary macroadenomas
por: Trofimiuk-Müldner, Małgorzata, et al.
Publicado: (2023)

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
por: von Guggenberg, Elisabeth, et al.
Publicado: (2021)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor imaging with [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH(2)]-exendin-4 for the detection of insulinoma
por: Sowa-Staszczak, Anna, et al.
Publicado: (2012)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

MON-300 AIP Gene Germline Mutations in Non-Selected Patients with Apparently Sporadic Pituitary Macrodenomas
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
por: Fröberg, Alida C., et al.
Publicado: (2009)

Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression
por: Summer, Dominik, et al.
Publicado: (2018)

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
por: Konijnenberg, Mark W, et al.
Publicado: (2014)

Development of the (99m)Tc-Labelled SST(2) Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
por: Novak, Doroteja, et al.
Publicado: (2023)

SAT-265 An Asynchronous Double Growth Hormone Secreting Pituitary Adenoma as a Cause of Rapid Tumor Regrowth After Initially Successful Surgery
por: Trofimiuk-Muldner, Malgorzata, et al.
Publicado: (2020)

Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK(2)R Cancer Theranostic Agents: A Preclinical Study
por: Nock, Berthold A., et al.
Publicado: (2022)

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

What Cut-off Value of 17-Hydroxyprogesterone Should Be an Indication to Perform a 250 µg Cosyntropin Stimulation Test When NCCAH Is Suspected? - a Retrospective Study
por: Domagala, Bartosz, et al.
Publicado: (2021)

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of (177)Lu-Labeled Peptide Analogs Targeting CCK2R
por: Hörmann, Anton Amadeus, et al.
Publicado: (2023)

Defects in GnRH Neuron Migration/Development and Hypothalamic-Pituitary Signaling Impact Clinical Variability of Kallmann Syndrome
por: Kałużna, Małgorzata, et al.
Publicado: (2021)

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles
por: Rangger, Christine, et al.
Publicado: (2013)

Yttrium-90 distribution following radiosynoviorthesis of the knee joint in rheumatoid arthritis patients: a SPECT/CT study
por: Bielińska, A., et al.
Publicado: (2014)

Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13
por: Klingler, Maximilian, et al.
Publicado: (2019)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
por: Klingler, Maximilian, et al.
Publicado: (2019)

Targeting prostate cancer with radiolabelled bombesins
por: Maina, Theodosia, et al.
Publicado: (2006)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

Pituitary insufficiency following traumatic thoracic injury in an adolescent male patient: A case report and literature review
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rbk495iqa00h8i0pen7638hds8